Aberrant promoter hypermethylation in biliary tract carcinoma
- PMID: 16858540
- DOI: 10.1007/s00534-005-1058-0
Aberrant promoter hypermethylation in biliary tract carcinoma
Abstract
Biliary tract carcinoma is a relatively rare tumor with a poor survival rate. The molecular biological mechanisms underlying the development of biliary tract carcinomas are not well understood. Promoter methylation is an important epigenetic mechanism for suppressing tumor-suppressor gene activity. There is limited information regarding the abnormal methylation of cancer-related genes in biliary tract carcinoma; however, a few insights have been obtained into the role of epigenetic silencing in the progression of biliary tract carcinoma. In this review, we summarize recent data on gene silencing by promoter hypermethylation, and we discuss the implications for biliary tract carcinomas.
Similar articles
-
Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.Ann Surg Oncol. 2005 May;12(5):354-63. doi: 10.1245/ASO.2005.07.020. Epub 2005 Mar 31. Ann Surg Oncol. 2005. PMID: 15915369
-
Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.Hum Pathol. 2009 Nov;40(11):1534-42. doi: 10.1016/j.humpath.2009.01.029. Epub 2009 Aug 19. Hum Pathol. 2009. PMID: 19695681
-
Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease.Clin Cancer Res. 2003 May;9(5):1773-8. Clin Cancer Res. 2003. PMID: 12738733
-
Role of epigenetic alterations in cholangiocarcinoma.J Hepatobiliary Pancreat Surg. 2006;13(4):274-9. doi: 10.1007/s00534-005-1055-3. J Hepatobiliary Pancreat Surg. 2006. PMID: 16858537 Review.
-
Epigenetic mechanisms in glioblastoma multiforme.Semin Cancer Biol. 2009 Jun;19(3):188-97. doi: 10.1016/j.semcancer.2009.02.005. Epub 2009 Feb 20. Semin Cancer Biol. 2009. PMID: 19429483 Review.
Cited by
-
Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis.Onco Targets Ther. 2014 Jul 10;7:1237-45. doi: 10.2147/OTT.S62103. eCollection 2014. Onco Targets Ther. 2014. PMID: 25053885 Free PMC article.
-
Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.Drug Des Devel Ther. 2015 Jun 3;9:2855-65. doi: 10.2147/DDDT.S76358. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26082616 Free PMC article.
-
Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer.World J Gastroenterol. 2010 Jan 21;16(3):330-8. doi: 10.3748/wjg.v16.i3.330. World J Gastroenterol. 2010. PMID: 20082478 Free PMC article.
-
Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.PLoS One. 2014 Sep 17;9(9):e107598. doi: 10.1371/journal.pone.0107598. eCollection 2014. PLoS One. 2014. PMID: 25229459 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials